@Gussington did generalise: pre commercialisation, where revenue is less than expenses such as R&D and the like, is always going to be a slow increase in market cap relative to the share price.
Correction: ... is sometimes going to be a slow increase in market cap ...
And sometimes a complete duster, which becomes worthless.
I'm not a particularly insightful investor / stock-watcher, but I can only conclude that in Biotech especially, stocks with merit far outnumber stocks which reach success.
I'm holding a modest parcel, and I've buying in and selling out of this company for years. Not now or ever would I consider it a safe bet, of even avoiding a crash to 25% of current valuation.
Is it worth the risk ...?
Oh, yeah ... sort of. If you like risk.
I don't mind jumping in where fools fear to tread.
In other words, invest in it if you can afford to lose it.
- Forums
- ASX - By Stock
- TAVR MARKET Superiority
@Gussington did generalise: pre commercialisation, where revenue...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M |
Open | High | Low | Value | Volume |
$18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $18.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.30 | 247 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 18.090 |
1 | 67 | 18.010 |
1 | 750 | 17.850 |
1 | 1500 | 17.800 |
1 | 1585 | 17.750 |
Price($) | Vol. | No. |
---|---|---|
18.300 | 247 | 2 |
18.540 | 25 | 1 |
18.690 | 550 | 1 |
19.000 | 437 | 1 |
19.700 | 100 | 1 |
Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |